Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

Home HITV Cancer Therapy What is Cancer Immunotherapy Dendritic Cells & The Immune System

Tuesday26 March 2019

Dendritic Cells & The Immune System

Dendritic Cells Initiate the Immune Response

Dendritic Cells Cancer
[ Image source from Penn Medicine, the University of Pennsylvania, US ]

Dendritic cells are professional antigen processing cells. They have a number of receptors that enhance the uptake of antigens, and they are specialized to convert these antigens into MHC-peptide complexes that can be recognized by lymphocytes. However, the dendritic cells need to do more than present antigens to T cells. They are also potent accessory cells that directly trigger and control responses by T cells and by all other types of lymphocytes.

Some early studies showed that dendritic cells carry on their surface high levels of major histocompatibility complex (MHC) products, which are critically recognized by T-lymphocytes. The high levels of MHC led Steinman to test these cells in the mixed leukocyte reaction (MLR), a well-known clinical assay for identifying the compatibility of tissue transplants between donors and recipients. At the time, this assay was known as mixed "lymphocyte" reaction, because it presumed that the B lymphocytes were presenting MHC products from the organ transplant donor to the recipient's T cells.

Instead, Steinman found that dendritic cells were the major stimulators and were unusually potent. In fact, a dendritic cell to T cell ratio of 1 to 100 sufficed to initiate vigorous and optimal responses. Moreover, the dendritic cells directly activated both the subset of helper T cells as well as the killer T cells. Once activated by dendritic cells, the T cells could also interact vigorously with other antigen presenting B cells and macrophages to produce additional immune responses from these cells.

The term "accessory" has since been replaced by the terms "professional" and "co-stimulatory," but the basic concept is unchanged. Dendritic cells provide the T cells with needed accessory or co-stimulatory substances, in addition to giving them a signal to begin to grow and function. For example, two of these specialized activities include the production of cytokines, like interleukin-12 and interferons, and the expression of a number of needed membrane molecules like CD40, CD70, and CD86.

Dendritic cells also influence the type or quality of the response. A T cell, for example, has to know whether the enemy is a virus that needs to be resisted with its own interferons and cytolytic molecules, or whether the pathogen is a parasite that requires a different set of protective cells to respond with antibodies. Therefore, when dendritic cells migrate to the body's pool of T cells areas in the lymph nodes, they need to orchestrate two fundamental components from the repertoire of lymphocyte functions. First the dendritic cells select the rare specific T cells from the assembled repertoire that recognize the specific peptide information the dendritic cells are carrying. Amazingly, only one in 10,000-100,000 of the T cells in that repertoire are able to respond to this information. Second, the rare T cells that are selected for expansion then differentiate into helper and killer T cells that have the appropriate functions to eliminate the infection or disease causing stimulus. After these two decisions have been made, the newly activated T cells leave the lymph node to return to the body surface or peripheral organ to eliminate the antigens. For orchestrating these various processes efficiently and precisely, the dendritic cells are considered to be "conductors of the immune orchestra."

Dendritic Cells and Immune Tolerance

Most studies have focused on the dendritic cells' role in activating T cells to resist foreign antigens, especially infections. Recent research in Steinman's laboratory, in close collaboration with other laboratories at Rockefeller, is showing that dendritic cells can also make the immune system tolerate harmless antigens, including those from the body's own tissues, cells, and proteins. This is necessary to keep the body from making an immune attack on itself.

The dendritic cell system appears to play a pivotal role in two kinds of immune tolerance. Usually, when young T cells are launched from the thymus, the dendritic cells participate in eliminating those cells bearing "self-reactive antigens" before they can harm the body's own tissues, a mechanism known as central tolerance.

Since some T cells may slip through this process, or other self-antigens do not access the thymus, or still others arise later in life, the dendritic cells also participate in the mechanism known as peripheral tolerance that restrains their activity. In the absence of infection or inflammation, the dendritic cells are in an immature state, but they are not quiescent. Like perpetual custodians, they clean house and collect trash. Sweeping non-stop through tissues and into lymphoid organs, the dendritic cells capture all kinds of antigens—the harmless self-antigens, those from dying cells, and the many nonpathogenic antigens encountered from the environment.

Two mechanisms have been identified that allow dendritic cells to induce tolerance. The antigen-loaded immature dendritic cells silence T cells by either deleting them or by inducing regulatory T cells that suppress the reactions of other immune cells. When the dendritic cells subsequently mature in response to infection, the preexisting tolerance nullifies any reaction to innocuous antigens and allows the dendritic cells to focus the immune response on the pathogen.

Other current research is providing clues about the dendritic cells' occasional failures to maintain tolerance. Failure to silence the immune system can lead to autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. If dendritic cells are too tolerant, this can create a permissive environment for chronic infectious agents, such as HIV. Infections and tumors can exploit the tolerogenic function of dendritic cells, shut down the normal immune defenses, and perpetuate disease.


HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks